Evidence map›Paper›PMID 42807827›Full record

ReviewFrontiers in oncology2026

Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma.

Enrico Amaducci, Michele Clerico, Davide Camoirano, Claudia Marinucci, Luisa Giaccone, Irene Dogliotti, Michele Dicataldo, Mattia D'Agostino, Benedetto Bruno, Federica Cavallo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Enrico AmaducciDivision of Hematology, Transplant and Cell Therapy Unit, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
Michele ClericoDivision of Hematology, Transplant and Cell Therapy Unit, Azienda Ospedaliero Universitaria (A.O.U) Città della Salute e della Scienza di Torino, Turin, Italy.
Davide CamoiranoDivision of Hematology, Transplant and Cell Therapy Unit, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
Claudia MarinucciDivision of Hematology, Transplant and Cell Therapy Unit, Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy.
Luisa GiacconeDivision of Hematology, Transplant and Cell Therapy Unit, Azienda Ospedaliero Universitaria (A.O.U) Città della Salute e della Scienza di Torino, Turin, Italy.
Irene DogliottiDivision of Hematology, Transplant and Cell Therapy Unit, Azienda Ospedaliero Universitaria (A.O.U) Città della Salute e della Scienza di Torino, Turin, Italy.
Michele DicataldoDivision of Hematology, Transplant and Cell Therapy Unit, Azienda Ospedaliero Universitaria (A.O.U) Città della Salute e della Scienza di Torino, Turin, Italy.
Mattia D'AgostinoDivision of Hematology, Transplant and Cell Therapy Unit, Azienda Ospedaliero Universitaria (A.O.U) Città della Salute e della Scienza di Torino, Turin, Italy.
Benedetto BrunoDivision of Hematology, Transplant and Cell Therapy Unit, Azienda Ospedaliero Universitaria (A.O.U) Città della Salute e della Scienza di Torino, Turin, Italy.
Federica CavalloDivision of Hematology, Transplant and Cell Therapy Unit, Azienda Ospedaliero Universitaria (A.O.U) Città della Salute e della Scienza di Torino, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic algorithm for relapsed or refractory large B-cell lymphoma (R/R LBCL) is rapidly evolving. Pivotal Phase III trials, ZUMA-7 and TRANSFORM, have established second-line CD19-directed CAR T-cell therapies (axi-cel and liso-cel) as standard of care for primary refractory or early-relapsing disease, displaying superior survival outcomes compared with salvage chemoimmunotherapy followed by autologous hematopoietic stem cells transplantation (auto-HSCT) which is now limited to late relapses. However, clinical management of R/R LBCL becomes highly complex in peculiar settings, especially in case of multiple relapses even after CAR T-cell therapy, as described in our clinical case of secondary central nervous system disease relapse. Allogeneic HSCT remains a niche consolidative strategy exclusively for fit patients lacking other therapeutic options. Moving forward, novel bioengineering approaches, including dual-targeting, memory-enriched and "armored" CARs, aim to overcome current resistance mechanisms and redefine future clinical practice.

Indexed as

B-cellCAR T-cell therapyhematopoietic stem cell transplant (HSCT)large B cell lymphomanew therapeutic agentssecondary central nervous system lymphomatransplantation

Identifiers

PMID42807827
PMCPMC13617608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.